<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964180</url>
  </required_header>
  <id_info>
    <org_study_id>analgesia LC</org_study_id>
    <nct_id>NCT04964180</nct_id>
  </id_info>
  <brief_title>Rectal Indomethacin Versus Intraperitoneal Lidocaine for Analgesia After Laparoscopic Cholecystectomy</brief_title>
  <official_title>Rectal Indomethacin Versus Intraperitoneal Lidocaine for Analgesia After Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Valley University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Valley University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hospitals, Qena, Egypt in period between May 2020 to May 2021.eighty patients was scheduled&#xD;
      to elective laparoscopic cholecystectomy , divided Into two groups randomly using closed&#xD;
      envelop method. Group IP lidocaine(40 patients ) received 200 ml saline containing 200 mg&#xD;
      2%lidocaine immediately after abdominal cO2 insufflation( pneumoperitoneum) the surgeon&#xD;
      sprayed the total solution on the upper surface of the liver under the right subdiaphragmatic&#xD;
      space, left subdiaphragmatic space and around the cholecystectomy site , all patients were&#xD;
      maintained in trendelenberg position.&#xD;
&#xD;
      At the end of the laparoscopic procedure, group indomethacin (40 patients) recived two 100 mg&#xD;
      indomethacin rectal suppositories 2 hours prior to surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Actual">June 20, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS scores postoperative</measure>
    <time_frame>24 hours posoperative</time_frame>
    <description>a standard 10-cm VAS was used, where one end of the scale represented no pain (0 cm), and the other end the most severe pain imaginable (10 cm), the distance in centimeters being taken as the pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative opoiods analgesics requirements</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>we used (iv pethidine )whenever the patient complained of pain. IV pethidine injection 25-50 mg was given as rescue analgesic whenever the patient experienced pain ≥ to 5 VAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain starting time after surgery and Pethidine required first time.</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Pain starting time after surgery and Pethidine required first time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Post-Operative Pain</condition>
  <arm_group>
    <arm_group_label>indomethacin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group indomethacin (40 patients) recived two 100 mg indomethacin rectal suppositories 2 hours prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intraperitoneal lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 ml saline containing 200 mg 2%lidocaine immediately after abdominal cO2 insufflation( pneumoperitoneum) the surgeon sprayed the total solution on the upper surface of the liver under the right subdiaphragmatic space, left subdiaphragmatic space and around the cholecystectomy site , all patients were maintained in trendelenberg position</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin suppository</intervention_name>
    <description>two 100 mg indomethacin rectal suppositories 2 hours prior to surgery</description>
    <arm_group_label>indomethacin group</arm_group_label>
    <other_name>Indocid suppository</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 2% Injectable Solution</intervention_name>
    <description>200 ml saline containing 200 mg 2%lidocaine intraperitoneal insilltation</description>
    <arm_group_label>intraperitoneal lidocaine</arm_group_label>
    <other_name>lidocaine HCL 2%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  .ASA physical status 1-2 patients.&#xD;
&#xD;
          -  18-60 years old .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  using or allergic to nonsteroidal anti inflammatory drugs (NSAIDs) or aspirin .&#xD;
&#xD;
          -  history of serious hepatic disease.&#xD;
&#xD;
          -  renal or gastrointestinal disease.&#xD;
&#xD;
          -  bleeding disorder.&#xD;
&#xD;
          -  body mass index BMI &lt;18 or ˃30 m2/kg.&#xD;
&#xD;
          -  history of abdominal surgery or chronic pain disorder other than gallbladder.&#xD;
&#xD;
          -  disease or allergy to lidocaine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gad sayed Gad</name>
      <address>
        <city>Qinā</city>
        <state>Qena</state>
        <zip>83511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Valley University</investigator_affiliation>
    <investigator_full_name>Gad Sayed Gad</investigator_full_name>
    <investigator_title>assisstant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

